Author

Angelica Loskog

Observed names: A Loskog, A Löskog, A S I Loskog, A. Loskog, A. S. I. Loskog, A. SI. Loskog, ANGELICA LOSKOG, Angelica S I Loskog, Angelica S Loskog, Angelica S. I. Loskog, Angelica S.I. Loskog, Angelica SI Loskog, Angelica SI. Loskog, Angelica Sara Ingrid Loskog, Loskog, A., Loskog, Angelica

Institutions: Uppsala University, Science for Life Laboratory

Observed institutions: Uppsala University, St. Jude Children's Research Hospital, University of Helsinki, Uppsala University Hospital, University of Crete, Baylor College of Medicine, Science for Life Laboratory, Helsinki University Hospital, FORTH Institute of Molecular Biology and Biotechnology, Institute for Molecular Medicine Finland, Swedish Cancer Society

ORCID: 0000-0001-8583-6138

Observed ORCID: 0000-0001-8583-6138

OpenAlex ID: A5063027590

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

2020 · Alireza Labani-Motlagh, Mehrnoush Ashja-Mahdavi, et al. · Frontiers in Immunology · 792

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

2012 · Moa Fransson, Elena Piras, et al. · Journal of Neuroinflammation · 383

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

2018 · Gunilla Enblad, Hannah Karlsson, et al. · Clinical Cancer Research · 285

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

2016 · Emma Eriksson, Jessica Wenthe, et al. · Journal of Translational Medicine · 235

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

2010 · Sara M. Mangsbo, Linda C. Sandin, et al. · Journal of Immunotherapy · 204

VEGF suppresses T‐lymphocyte infiltration in the tumor microenvironment through inhibition of NF‐κB‐induced endothelial activation

2014 · Hua Huang, Elise Langenkamp, et al. · The FASEB Journal · 195

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

2006 · A Loskog, V Giandomenico, et al. · Leukemia · 191

Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus

2012 · Iulia Diaconu, Vincenzo Cerullo, et al. · Cancer Research · 168

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus

2017 · Emma Eriksson, Ioanna Milenova, et al. · Clinical Cancer Research · 154

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

2011 · J D Dias, O Hemminki, et al. · Gene Therapy · 153

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

2013 · Lisa Christiansson, Stina Söderlund, et al. · PLoS ONE · 134

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

2017 · Tanja Kaartinen, Annu Luostarinen, et al. · Cytotherapy · 129

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

2020 · Eric K. Rowinsky, Agne Paner, et al. · Investigational New Drugs · 121

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

2015 · Hannah Karlsson, Emma Svensson, et al. · PLoS ONE · 116

AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial

2010 · Per-Uno Malmström, Angelica S.I. Loskog, et al. · Clinical Cancer Research · 116

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

2018 · Jean-Marc Hoffmann, Maria-Luisa Schubert, et al. · Frontiers in Immunology · 108

Human Bladder Carcinoma is Dominated by T-Regulatory Cells and Th1 Inhibitory Cytokines

2006 · Angelica Loskog, Christina Ninalga, et al. · The Journal of Urology · 107

Assessing tissue damage in multiple sclerosis: a biomarker approach

2014 · J. Burman, H. Zetterberg, et al. · Acta Neurologica Scandinavica · 91

T regulatory cells control T‐cell proliferation partly by the release of soluble CD25 in patients with B‐cell malignancies

2010 · Camilla A. Lindqvist, Lisa H. Christiansson, et al. · Immunology · 91

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study

2024 · Benjamin L Musher, Eric K Rowinsky, et al. · The Lancet Oncology · 89

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

2014 · Linda C Sandin, Fredrik Eriksson, et al. · OncoImmunology · 88

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

2016 · E Eriksson, R Moreno, et al. · Gene Therapy · 80

Adenovirus CD40 Ligand Gene Therapy Counteracts Immune Escape Mechanisms in the Tumor Microenvironment

2004 · Angelica Loskog, Helena Dzojic, et al. · The Journal of Immunology · 77

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

2015 · Lisa Christiansson, Stina Söderlund, et al. · Molecular Cancer Therapeutics · 71

Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma

2013 · Sara Westberg, Arian Sadeghi, et al. · Journal of Immunotherapy · 67

Works count: 332

Citation count: 6,234

H-index: 42

I10-index: 83